LYSOGENE This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
LYSOGENE is a biotechnology company specializing in the research and development of gene therapies for the treatment of rare neurodegenerative diseases.
The company now has 2 drug candidates in clinical development of which 1 in phase 2/3 (LYS-SAF302 for the treatment of Sanfilippo syndrome type A) and 1 in phase 1/2 (LYS-GM101 for the treatment of GM1 gangliosidosis).
| 1st Jan change | Capi. | |
|---|---|---|
| -17.60% | 11.52B | |
| +39.11% | 3.27B | |
| -20.67% | 2.02B | |
| -29.30% | 1.44B | |
| +11.45% | 1.01B | |
| -6.33% | 719M | |
| -30.75% | 418M | |
| -51.02% | 339M | |
| -2.58% | 284M |
